Memorial Sloan Kettering

Site:	Memorial Sloan Kettering	Go to their website
Address:	1275 York Ave
City:	New York
State:	NY
Zip:	10065
Country:	USA

45 trials at this site

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
1	GDC-0449 and RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Completed	Closed	GDC-0449 + RO4929097	NCT01154452
1b/2	MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Imatinib + MEK162	NCT01991379
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Completed	Closed	Nivolumab + Ipilimumab	NCT02500797
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Active, not recruiting	Active, not recruiting	Bezuclastinib plus Sunitinib	NCT05208047
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Active, not recruiting	Closed	INBRX-109 + Temozolomide	NCT03715933
1	Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody	Active, not recruiting	Closed	HuF9-G4	NCT02216409
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
1	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	Closed	PLX9486 + PLX3397	NCT02401815
2	Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Not yet activated	Ripretinib plus Binimetinib	NCT05080621
1	Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Active, not recruiting	Closed	Nivolumab + BMS-986016	NCT01968109
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor	Completed	Closed	KW2450	NCT00921336
1	Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + MEK162	NCT01363232
2	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Ongoing, but not recruiting	Closed	Sorafenib (Nexavar, BAY 43-9006)	NCT00265798
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active, not recruiting	LOXO-101	NCT02576431
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862

Memorial Sloan Kettering

45 trials at this site

First | Previous | Page 2 of 3 | Next | Last